NOTCH3 Protein

NOTCH3 Protein

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">NOTCH3 Protein</th>
</tr>
<tr>
<td class="label">Strategy</td>
<td>Status</td>
</tr>
<tr>
<td class="label">[Gamma-secretase](/entities/gamma-secretase) inhibitors</td>
<td>Not beneficial</td>
</tr>
<tr>
<td class="label">Notch modulators</td>
<td>Research</td>
</tr>
<tr>
<td class="label">Anti-NOTCH3 antibodies</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">Gene therapy</td>
<td>Future</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Sarafan</td>
<td>NOTCH3</td>
</tr>
<tr>
<td class="label">Anti-NOTCH3 antibodies</td>
<td>NOTCH3 extracellular</td>
</tr>
<tr>
<td class="label">Gamma-secretase modulators</td>
<td>Gamma-secretase</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/autoimmune" style="color:#ef9a9a">Autoimmune</a>, <a href="/wiki/cancer" style="color:#ef9a9a">Cancer</a>, <a href="/wiki/carcinoma" style="color:#ef9a9a">Carcinoma</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">57 edges</a></td>
</tr>
</table>

Introduction

...

NOTCH3 Protein

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">NOTCH3 Protein</th>
</tr>
<tr>
<td class="label">Strategy</td>
<td>Status</td>
</tr>
<tr>
<td class="label">[Gamma-secretase](/entities/gamma-secretase) inhibitors</td>
<td>Not beneficial</td>
</tr>
<tr>
<td class="label">Notch modulators</td>
<td>Research</td>
</tr>
<tr>
<td class="label">Anti-NOTCH3 antibodies</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">Gene therapy</td>
<td>Future</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Sarafan</td>
<td>NOTCH3</td>
</tr>
<tr>
<td class="label">Anti-NOTCH3 antibodies</td>
<td>NOTCH3 extracellular</td>
</tr>
<tr>
<td class="label">Gamma-secretase modulators</td>
<td>Gamma-secretase</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/autoimmune" style="color:#ef9a9a">Autoimmune</a>, <a href="/wiki/cancer" style="color:#ef9a9a">Cancer</a>, <a href="/wiki/carcinoma" style="color:#ef9a9a">Carcinoma</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">57 edges</a></td>
</tr>
</table>

Introduction

Notch3 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

NOTCH3 is a transmembrane receptor protein involved in cell-cell communication through a conserved signaling pathway. Mutations in NOTCH3 cause CADASIL (Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy), the most common inherited form of vascular dementia.

Normal Function: NOTCH3 signaling regulates vascular smooth muscle cell development and maintenance. The extracellular domain accumulates with age in normal brains but dramatically accelerates in CADASIL.

Role in Neurodegeneration:

• NOTCH3 mutations cause CADASIL, characterized by:
• Recurrent subcortical ischemic strokes
• Cognitive decline and dementia
• Migraine with aura
• White matter lesions on MRI
• NOTCH3 may influence amyloid processing in AD
• NOTCH3 polymorphisms affect risk for sporadic AD

NOTCH3 is a member of the Notch receptor family involved in cell fate determination and vascular development. Mutations in NOTCH3 cause CADASIL (Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy), a hereditary vascular dementia.

Structure

NOTCH3 is a 2,321 amino acid type I transmembrane receptor:

• Extracellular domain (1-1643): Contains 34 EGF-like repeats, 3 LIN-12 Notch repeats
• Transmembrane domain (1644-1666): Single pass
• Intracellular domain (1667-2321): Transcriptional activator domain (RAM, Ankyrin repeats, TAD)
• Molecular weight: ~270 kDa (full-length)

Key Features:

• EGF-like repeats: Calcium-binding (cbEGF) and non-calcium-binding
• Cysteine residues: Form disulfide bonds for stability

Normal Function

NOTCH3 is primarily expressed in vascular smooth muscle cells and [pericytes](/cell-types/pericytes):

Key Functions:

Vascular Development: Essential for blood vessel formation

Smooth Muscle Cell Maintenance: Regulates vascular homeostasis

Cell Fate Decisions: Lateral inhibition via Delta-like ligands

Angiogenesis: Modulates blood vessel formation

[Blood-Brain Barrier](/entities/blood-brain-barrier): Regulates endothelial-pericyte interactions

Expression:

• Vascular smooth muscle cells (highest)
• [Pericytes](/cell-types/pericytes)
• Some [neurons](/entities/neurons)

Role in Disease

CADASIL

NOTCH3 is the causative gene for CADASIL:

• Inheritance: Autosomal dominant
• Mutations: Over 200 missense mutations, mostly in EGF-like domains
• Pathology:
• Granular osmiophilic deposits (GOM) in vessel walls
• Smooth muscle cell degeneration
• Lacunar infarcts, white matter lesions
• Symptoms: Migraine, strokes, dementia

Alzheimer's Disease

• NOTCH3 variants may modify risk
• Vascular contributions to AD
• Possible therapeutic target

Other Associations:

• Variants in AD/FTD: Rare risk modifiers
• Cancer: Context-dependent roles

Therapeutic Targeting

Key Publications

Joutel et al. (1996) "NOTCH3 mutations in CADASIL" Nature[@gridley1997]

Gridley (2007) "Notch signaling in vascular development" Organogenesis[@kopan2004]

Background

The study of Notch3 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

See Also

• NOTCH3 Gene
• [CADASIL](/diseases/cadasil)
• [Vascular Dementia](/diseases/vascular-dementia)
• [Blood-Brain Barrier](/entities/blood-brain-barrier)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Stroke](/diseases/stroke)

External Links

• [NCBI: NOTCH3](https://www.ncbi.nlm.nih.gov/gene/4854)
• [UniProt: Q9UM47](https://www.uniprot.org/uniprot/Q9UM47)
• [OMIM: 600276](https://www.omim.org/entry/600276)

Therapeutic Implications

NOTCH3 is a validated target for CADASIL treatment. Several therapeutic approaches are being explored, including gamma-secretase inhibitors that reduce NOTCH3 signaling, monoclonal antibodies against the NOTCH3 extracellular domain, and gene therapy approaches to correct CADASIL-causing mutations.

Research Directions

Research on NOTCH3 focuses on understanding how specific cysteine mutations cause CADASIL. Studies are investigating the role of NOTCH3 in vascular smooth muscle cell maintenance and blood-brain barrier function. Additionally, research is exploring biomarkers for CADASIL progression and treatment response.

Molecular Function

NOTCH3 is a single-pass transmembrane receptor belonging to the NOTCH family (NOTCH1-4 in mammals)[@gridley1997]. It transduces signals between adjacent cells through conserved ligand (Delta/Jagged)-mediated interactions[@kopan2004].

Structure

NOTCH3 contains:

• Extracellular domain (NECD): EGF-like repeats for ligand binding
• Transmembrane domain: anchors the receptor
• Intracellular domain (NICD): translocates to nucleus for signaling

Signaling Pathway

NOTCH3 signaling involves:

Ligand binding → proteolytic cleavage (ADAM10/17, γ-secretase)

NICD release and nuclear translocation

Transcriptional activation with CSL/RBP-Jκ

Role in Cerebral Vasculature

Vascular Smooth Muscle Cells

NOTCH3 is predominantly expressed in vascular smooth muscle cells (VSMCs) where it:

• Maintains VSMC contractility
• Regulates blood flow
• Controls vascular development[@domenga2004]

CADASIL

CADASIL (Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy) is caused by NOTCH3 mutations - the most common hereditary stroke disorder[@joutel1996].

• Over 200 NOTCH3 mutations identified
• Accumulation of NOTCH3 extracellular domain in small arteries
• Leads to vessel wall thickening, lacunar strokes, and vascular dementia

Role in Neurodegeneration

Alzheimer's Disease

NOTCH3 interactions with AD include:

• γ-secretase processes both NOTCH and amyloid precursor protein (APP)
• NOTCH signaling affects amyloid-β production
• Vascular NOTCH3 dysfunction may contribute to CAA[@marvie2004]

Parkinson's Disease

In PD, NOTCH3 may play roles in:

• Nigral neuron development and maintenance
• Glial cell function
• [Neuroinflammation](/mechanisms/neuroinflammation)

Therapeutic Implications

• γ-secretase inhibitors: affect both APP and NOTCH processing
• NOTCH3-specific antibodies: being developed for CADASIL
• Vascular protective strategies: for CADASIL treatment

References

[@gridley1997]: Gridley, T. [Notch genes in vertebrate development](https://pubmed.ncbi.nlm.nih.gov/9275203/). Cell. 1997.
[@kopan2004]: Kopan, R. et al. [Notch signaling](https://pubmed.ncbi.nlm.nih.gov/15469841/). Cell. 2004.
[@domenga2004]: Domenga, V. et al. [Notch3 is required for vascular development](https://pubmed.ncbi.nlm.nih.gov/15286739/). Development. 2004.
[@joutel1996]: Joutel, A. et al. [CADASIL: Notch3 mutations](https://pubmed.ncbi.nlm.nih.gov/8852660/). Nature. 1996.
[@marvie2004]: Marvie, P. et al. [Notch3 and Alzheimer's disease](https://pubmed.ncbi.nlm.nih.gov/12646242/). Neurobiology of Aging. 2004.